QIAGEN (QGEN)
(Delayed Data from NYSE)
$41.52 USD
-0.37 (-0.88%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $41.52 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
QGEN 41.52 -0.37(-0.88%)
Will QGEN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for QGEN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for QGEN
Unveiling Qiagen (QGEN) Q1 Outlook: Wall Street Estimates for Key Metrics
QIAGEN (QGEN) Boosts Cancer Research Suite With New Launches
QGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
QIAGEN (QGEN) Unveils QIAstat-Dx Analyzer With Remote Access
QIAGEN (QGEN) Partners With IPPA to Raise TB Screening Awareness
Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test
Other News for QGEN
QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance
Bank of America Securities Reaffirms Their Buy Rating on Qiagen (QGEN)
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Innate Pharma SA (OtherIPHYF) and Neumora Therapeutics, Inc. (NMRA)
Deutsche Bank Remains a Buy on Qiagen (QGEN)
QIAGEN N.V. to release results for Q1 2024 and hold webcast